Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M
Upstream Bio will use its IPO haul to continue clinical testing of verekitug, which it contends could be a better treatment option for severe asthma compared to a commercialized Amgen and AstraZeneca drug. CAMP4 Therapeutics and CeriBell also priced IPOs to join the public markets.